AstraZeneca, a leading global biopharmaceutical company, has announced plans to invest $300 million in a new 84,000-square-foot manufacturing facility in Rockville, MD. The state-of-the-art facility will serve as the launch site for the company’s cell therapy platforms in the U.S., supporting critical cancer trials and future commercial supply. Located at 9950 Medical Center Dr., this cutting-edge facility is expected to be operational by 2026.
The investment will also bring over 150 highly skilled jobs to Maryland as the site initially focuses on manufacturing T-cell therapies for clinical trials worldwide. As demand grows, there may be opportunities for expansion into other disease areas.
Strategically located within Maryland’s life sciences corridor and less than five miles from one of AstraZeneca’s global R&D centers, this new facility further solidifies their commitment to innovation and growth. In addition to Rockville, AstraZeneca recently signed a full-building lease in Gaithersburg.
According to Governor Wes Moore of Maryland: “This significant investment by AstraZeneca is a testament not only to our state’s strong life sciences sector but also our shared dedication towards advancing healthcare through groundbreaking research and development.” With this expansion of their Montgomery County operations underway,AstraZenecais poisedto maintain its leadership positioninthe industryandstrengthenitscompetitive edge.
